-
Tytuł:
-
Clinical impact of hypothalamic-pituitary disorders after conformal radiation therapy for pediatric low-grade glioma or ependymoma.
-
Autorzy:
-
van Iersel L; Division of Endocrinology, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
van Santen HM; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
Potter B; Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Li Z; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Conklin HM; Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Zhang H; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Chemaitilly W; Division of Endocrinology, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Merchant TE; Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
-
Źródło:
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Dec; Vol. 67 (12), pp. e28723. Date of Electronic Publication: 2020 Oct 10.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Hoboken, N.J. : John Wiley, c 2004-
-
MeSH Terms:
-
Ependymoma/*radiotherapy
Glioma/*radiotherapy
Growth Disorders/*pathology
Human Growth Hormone/*therapeutic use
Hypothalamic Diseases/*pathology
Pituitary Diseases/*pathology
Radiotherapy, Conformal/*adverse effects
Adolescent ; Adult ; Child ; Child, Preschool ; Ependymoma/pathology ; Female ; Follow-Up Studies ; Glioma/pathology ; Growth Disorders/drug therapy ; Growth Disorders/etiology ; Humans ; Hypothalamic Diseases/drug therapy ; Hypothalamic Diseases/etiology ; Infant ; Male ; Pituitary Diseases/drug therapy ; Pituitary Diseases/etiology ; Prognosis ; Retrospective Studies ; Young Adult
-
References:
-
Clement SC, Schouten-van Meeteren AY, Boot AM, et al. Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study. J Clin Oncol. 2016;34(36):4362-4370.
Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761-2784.
Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015;33(5):492-500.
Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921.
Nieves-Martinez E, Sonntag WE, Wilson A, et al. Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation. J Endocrinol. 2010;204(1):31-36.
Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89(10):5003-5012.
Follin C, Thilen U, Osterberg K, Bjork J, Erfurth EM. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2010;95(8):3726-3735.
van den Heijkant S, Hoorweg-Nijman G, Huisman J, et al. Effects of growth hormone therapy on bone mass, metabolic balance, and well-being in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2011;33(6):e231-238.
Tamhane S, Sfeir JG, Kittah NEN, et al. GH therapy in childhood cancer survivors: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(8):2794-2801.
Hudson MM, Ness KK, Nolan VG, et al. Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. Pediatr Blood Cancer. 2011;56(5):825-836.
Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152-2167.
Armstrong GT, Conklin HM, Huang S, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol. 2011;13(2):223-234.
Gan HW, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787-3799.
Vatner RE, Niemierko A, Misra M, et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Clin Oncol. 2018;36(28):2854-2862.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011;29(36):4776-4780.
Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab. 2003;88(8):3682-3689.
Cohen LE, Gordon JH, Popovsky EY, et al. Bone density in post-pubertal adolescent survivors of childhood brain tumors. Pediatr Blood Cancer. 2012;58(6):959-963.
Green DM, Cox CL, Zhu L, et al. Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2012;30(3):246-255.
Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - from the St. Jude Lifetime Cohort. Br J Haematol. 2014;165(3):364-374.
Murray RD, Darzy KH, Gleeson HK, Shalet SM. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab. 2002;87(1):129-135.
Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, et al. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. Eur J Endocrinol. 2018;178(1):11-22.
Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36(21):2181-2189.
Cheung YT, Brinkman TM, Li C, et al. Chronic health conditions and neurocognitive function in aging survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2018;110(4):411-419.
Nyberg F, Hallberg M. Growth hormone and cognitive function. Nat Rev Endocrinol. 2013;9(6):357-365.
Arwert LI, Deijen JB, Witlox J, Drent ML. The influence of growth hormone (GH) substitution on patient-reported outcomes and cognitive functions in GH-deficient patients: a meta-analysis. Growth Horm IGF Res. 2005;15(1):47-54.
Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden RW, et al. Neonatal screening for congenital hypothyroidism in the Netherlands: cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab. 2007;92(3):919-924.
Tiemensma J, Andela CD, Biermasz NR, Romijn JA, Pereira AM. Mild cognitive deficits in patients with primary adrenal insufficiency. Psychoneuroendocrinology. 2016;63:170-177.
Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2014;99(6):2030-2037.
-
Contributed Indexing:
-
Keywords: central nervous system neoplasms; childhood cancer survivor; hypopituitarism; radiotherapy
-
Substance Nomenclature:
-
12629-01-5 (Human Growth Hormone)
-
Entry Date(s):
-
Date Created: 20201010 Date Completed: 20210125 Latest Revision: 20210125
-
Update Code:
-
20240105
-
DOI:
-
10.1002/pbc.28723
-
PMID:
-
33037871
-
Background: To determine the impact of hypothalamic-pituitary (HP) disorders on health outcomes in children and adolescents who received conformal radiation therapy (RT) for central nervous system tumors.
Procedure: Cohort study including 355 patients (age ≤25 years at diagnosis) treated with high-dose (50.4-59.4 Gy) RT using photons for low-grade glioma or ependymoma. Patients (median age, 6.4 years at RT) received systematic endocrine follow-up (median duration, 10.1 years; range, 0.1-19.6). Associations between HP disorders and adverse health outcomes were determined by multivariable analysis.
Results: Prevalence was 37.2% for growth hormone deficiency (GHD), 17.7% for gonadotropin deficiency (LH/FSHD), 14.9% for thyroid-stimulating hormone deficiency (TSHD), 10.3% for adrenocorticotropic hormone deficiency (ACTHD), and 12.6% for central precocious puberty (CPP). Hypothalamus mean dose ≥ 36 Gy was associated with higher odds of any deficiency. GHD was associated with short stature (OR 2.77; 95% CI 1.34-5.70), low bone mineral density (OR 3.47; 95% CI 1.16-10.40), and TSHD with dyslipidemia (OR 5.54; 95% CI 1.66-18.52). Patients with ACTHD and CPP had lower intelligence quotient scores, and memory scores were impaired in patients with GHD (P = 0.02). Treatment of GHD was not associated with increased risk for tumor recurrence, secondary tumors, or mortality.
Conclusions: HP disorders occur frequently in patients receiving high-dose RT and are related to physical and neurocognitive well-being. Future studies are needed to assess whether further optimization of endocrine management yields better health outcomes.
(© 2020 Wiley Periodicals LLC.)